Cost-Effective Innovation

November 12, 2015
Tim Mayleben
President and Chief Executive Officer

By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs.  We’ve been bombarded with commentary, articles and opinion pieces on these drugs and their high prices.  The PCSK9 inhibitors – injectable, biologic drugs that dramatically lower LDL-cholesterol – appear to be very efficacious.  But these drugs are priced at… Read More

Reflections One Year Post-IPO

June 26, 2014
Tim Mayleben
President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C) lowering therapy for patients with hypercholesterolemia who are unable to tolerate a statin. Since… Read More

Posted In: Company News

ACC.14: Spotlighting the Importance of Finding New Therapies for Statin Intolerant Patients

April 21, 2014
Roger Newton, PhD, FAHA
Executive Chairman and Chief Scientific Officer

Late last month, the American College of Cardiology (ACC) held its 63rd Annual Scientific Session & Expo with more than 13,000 cardiovascular experts coming together in Washington, D.C. As I have for many years, I traveled to ACC.14 with my Esperion colleagues to hear firsthand the latest research findings in the prevention, diagnosis and treatment… Read More

Beyond Statins: Providing an Alternative for LDL-C Lowering

April 9, 2014
Tim Mayleben
President and Chief Executive Officer

Brian Orelli’s recent article in BioWorld Insight, “Avoiding the PCSK9 frenzy with alternative drug targets,” highlights how the focus and excitement around the PCSK9 inhibitors reflects the high level of interest for effective alternatives to statins for low-density lipoprotein cholesterol (LDL-C) lowering. While the PCSK9 inhibitors—injectable biologic therapies—have demonstrated compelling efficacy, Orelli’s piece reminds us… Read More

A Conversation with Dr. Robert Eckel About Treating Patients with Both Diabetes and Hypercholesterolemia

March 28, 2014
Robert H. Eckel, MD
Professor of Medicine and holds the Charles A. Boettcher Endowed Chair in Atherosclerosis at the University of Colorado School of Medicine

In March 2014, Arteriosclerosis, Thrombosis, and Vascular Biology, a journal of the American Heart Association, published the results of ETC-1002-005, Esperion’s Phase 2a clinical study of ETC-1002 in patients with hypercholesterolemia and type 2 diabetes, along with an editorial about targeting low-density lipoprotein cholesterol (LDL-C) and diabetes in those patients. ETC-1002-005 was a randomized, double-blind,… Read More

Why we Like the New AHA/ACC Cholesterol Guidelines

November 17, 2013
Tim Mayleben
President and Chief Executive Officer

On November 12, the American College of Cardiology (ACC) and the American Heart Association (AHA) released new guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) risk in adults. These guidelines represent an important shift from past cholesterol guidelines and are of particular interest to Esperion because we are working to… Read More